$AMBS The data demonstrated that chronic delivery
Post# of 103013
(Total Views: 256)
Posted On: 06/06/2018 8:17:59 PM
$AMBS The data demonstrated that chronic delivery of human recombinant MANF (hrMANF) starting two days after stroke-like injury in the distal middle cerebral artery occlusion (dMCAo) rat model of ischemia-reperfusion injury resulted in statistically significant improvement in functional outcomes at each time points assessed (7 days, 14 days and 24 days post-treatment). MANF also demonstrated efficacy in animal models of other ischemia-reperfusion related conditions including retinal artery occlusion (RAO), and myocardial infarction (heart attack). MANF's emerging role as an immunomodulatory protein further supports its development as a potential treatment for stroke.
https://investorshangout.com/The-Hot-Zone-69120/
$AMBS
https://investorshangout.com/The-Hot-Zone-69120/
$AMBS
(0)
(0)
Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!
Scroll down for more posts ▼